Actimmune, also known as interferon gamma-1b, is a medication used to treat chronic granulomatous disease (CGD) and to reduce the frequency of infections in patients with severe, difficult-to-treat osteopetrosis [1]. CGD is a rare genetic disorder that affects the immune system's ability to fight off infections, while osteopetrosis is a condition where bones become too dense.
How does Actimmune work?
Actimmune is a recombinant form of human interferon gamma. Interferon gamma is a naturally occurring protein that plays a role in the immune system's response to infections [1]. By providing an external source of interferon gamma, Actimmune helps to enhance the immune system's ability to fight certain types of infections, particularly those caused by bacteria and fungi [1]. For patients with CGD, it helps to improve the function of phagocytes, a type of white blood cell that engulfs and destroys pathogens.
When does Actimmune's patent exclusivity end?
Information regarding the specific patent expiration dates for Actimmune is not publicly available in the provided context. Patent information for pharmaceuticals can be complex, often involving multiple patents for the drug itself, its manufacturing process, or specific uses. For detailed patent status and expiry timelines, resources like DrugPatentWatch.com [2] can be consulted.
What are the potential side effects of Actimmune?
Common side effects of Actimmune can include flu-like symptoms such as fever, headache, chills, fatigue, and muscle aches. Other potential side effects may include nausea, vomiting, diarrhea, rash, and pain at the injection site [1]. More serious side effects, though less common, can occur and may require medical attention.
Who manufactures Actimmune?
Actimmune is manufactured by Horizon Therapeutics [1].
What are the treatment guidelines for Actimmune?
Actimmune is typically administered by subcutaneous injection. The dosage and frequency of administration are determined by a healthcare professional based on the patient's condition and response to treatment [1]. Regular monitoring by a healthcare provider is important during treatment.
Are there alternatives to Actimmune for CGD or osteopetrosis?
Treatment for CGD and osteopetrosis can involve various approaches depending on the specific case. For CGD, hematopoietic stem cell transplantation is a potential curative option for some patients. Supportive care, including prophylactic antibiotics and antifungals, is also a crucial part of management. For osteopetrosis, treatment focuses on managing complications and may involve supportive measures or, in severe cases, hematopoietic stem cell transplantation [3]. The suitability of alternative treatments is determined on an individual basis by medical professionals.
---
Sources:
1. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/actimmune-interferon-gamma-1b-information
2. https://drugpatentwatch.com/
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteopetrosis. https://www.niams.nih.gov/health-topics/osteopetrosis